Edition:
United States

Biotechnology & Medical Research

Page 1

Kang Stem Biotech receives Russia patent

9:43pm EST

Jan 17 (Reuters) - Kang Stem Biotech Co Ltd <217730.KQ> ::Says it received Russia patent on Jan. 17, for method of preparing induced neural stem cells reprogrammed from non-neuronal cells using hmga2.

Allergan, Ironwood Announce Settlement With Sun Pharma

8:30am EST

Jan 16 (Reuters) - Allergan Plc ::IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION.SAYS PER SETTLEMENT TERMS, IRONWOOD, CO TO GRANT UNITS OF SUN PHARMA LICENSE TO MARKET GENERIC VERSION OF LINZESS IN U.S. BEGINNING FEB 1, 2031​.SAYS ‍ADDITIONAL DETAILS REGARDING SETTLEMENT WERE NOT DISCLOSED​.SAYS IRONWOOD PHARMACEUTICALS, CO ANNOUNCED COMPANIES REACHED AN AGREEMENT WITH WHOLLY-OWNED UNITS OF SUN PHARMACEUTICAL INDUSTRIES.SAYS ‍AS A RESULT OF SETTLEMENT, ALL HATCH-WAXMAN LITIGATION BETWEEN COMPANIES AND SUN PHARMA REGARDING LINZESS PATENTS TO BE DISMISSED​.

Athenex Receives Positive Feedback From FDA On The Design Of Phase III Clinical Trial For Oraxol

8:00am EST

Jan 16 (Reuters) - Athenex Inc ::ATHENEX RECEIVES POSITIVE FEEDBACK FROM FDA ON THE DESIGN OF PHASE III CLINICAL TRIAL FOR ORAXOL.ATHENEX INC - SECOND INTERIM ANALYSIS OF ORAXOL PHASE III CLINICAL STUDY BASED ON 180 EVALUABLE PATIENTS IS PLANNED FOR MIDDLE OF 2018.

Tenax Therapeutics Announces Plan To Develop Levosimendan For A Pulmonary Hypertension Indication With No FDA Approved Therapies

7:45am EST

Jan 16 (Reuters) - Tenax Therapeutics Inc ::TENAX THERAPEUTICS ANNOUNCES PLAN TO DEVELOP LEVOSIMENDAN FOR A PULMONARY HYPERTENSION INDICATION WITH NO FDA APPROVED THERAPIES.TENAX THERAPEUTICS - PHASE 2 TRIAL TO INVESTIGATE LEVOSIMENDAN IN PULMONARY HYPERTENSION-WHO GROUP 2 PATIENTS WITH PRESERVED EJECTION FRACTION.TENAX THERAPEUTICS INC - PLANS TO INITIATE PHASE 2 TRIAL IN PH-HFPEF PATIENTS IN EARLY PART OF Q3 OF 2018.TENAX THERAPEUTICS INC - ‍PRE-IND MEETING IS SCHEDULED WITH FDA TO DISCUSS DEVELOPMENT OF LEVOSIMENDAN IN PH-HFPEF IN COMING MONTHS​.

RepliCel Life Sciences Lands Commitment For Key Investment Partnership

6:00am EST

Jan 16 (Reuters) - Replicel Life Sciences Inc ::REPLICEL LIFE SCIENCES LANDS COMMITMENT FOR KEY INVESTMENT PARTNERSHIP.REPLICEL LIFE SCIENCES SAYS DEAL REFLECTED IN TERM SHEET INVOLVES UP-FRONT INVESTMENT OF $6.5 MILLION.REPLICEL LIFE SCIENCES - SIGNED BINDING TERM SHEET WITH YOFOTO (CHINA) HEALTH INDUSTRY TO FORM A STRATEGIC PARTNERSHIP IN GREATER CHINA.

Midatech Pharma Says Approval Of Investigational New Drug Application From US FDA To Conduct Study Of MTX110

2:00am EST

Jan 16 (Reuters) - Midatech Pharma Plc ::APPROVAL OF INVESTIGATIONAL NEW DRUG APPLICATION FROM US FDA TO CONDUCT A STUDY OF MTX110.MTX110 IS AN INVESTIGATIONAL NANO-INCLUSION PRODUCT, FOR TREATMENT OF FATAL CHILDHOOD BRAIN CANCER DIPG.

MolMed: Zalmoxis Can Be Reimbursed In Germany For EUR 163,900 Per Infusion

1:50am EST

Jan 16 (Reuters) - MOLECULAR MEDICINE SPA ::SAYS THAT AS OF JAN 15 ZALMOXIS CAN BE PRESCRIBED AND REIMBURSED IN GERMANY AT THE PRICE OF EUR 163,900 PER INFUSION.APPROVED DOSAGE FORESEES ONE OR MORE INFUSIONS, UP TO A MAXIMUM OF FOUR, TILL IMMUNE-RECONSTITUTION IS ACHIEVED.MOLMED WILL BE RESPONSIBLE FOR THE PRODUCTION AND SUPPLY OF ZALMOXIS, WHILE DOMPÉ FARMACEUTICI WILL CONDUCT ACTIVITIES AIMED AT MARKETING THE THERAPY IN GERMANY.DOMPÉ WILL PAY MOLMED A PURCHASE PRICE PROPORTIONAL TO THE REIMBURSED PRICE OF THE PRODUCT.

Neovacs ‍Granted A New Patent From Russian Federation Patent Office (Rospatent)​

1:00am EST

Jan 16 (Reuters) - NEOVACS SA ::‍GRANTED A NEW PATENT FROM RUSSIAN FEDERATION PATENT OFFICE (ROSPATENT)​.‍PATENT STRENGTHENS NEOVACS' INTERFERON ALPHA (IFNALPHA)-RELATED INTELLECTUAL PROPERTY PORTFOLIO​.‍PATENT UNTIL AT LEAST 2032.​.

Benitec Biopharma ‍Says U.S. FDA Granted Orphan Drug Designation To BB-301​

Sunday, 14 Jan 2018 04:57pm EST

Jan 15 (Reuters) - Benitec Biopharma Ltd ::‍U.S. FDA HAS GRANTED ORPHAN DRUG DESIGNATION TO BB-301 FOR TREATMENT OF OCULOPHARYNGEAL MUSCULAR DYSTROPHY(OPMD)​.

Concert Pharma Says FDA Granted Fast Track Designation To CTP-543

Friday, 12 Jan 2018 07:05am EST

Jan 12 (Reuters) - Concert Pharmaceuticals Inc ::FDA GRANTS FAST TRACK DESIGNATION TO CONCERT PHARMACEUTICALS’ CTP-543 FOR THE TREATMENT OF ALOPECIA AREATA.CONCERT PHARMA SAYS U.S. FDA GRANTED FAST TRACK DESIGNATION FOR CO'S CTP-543.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary